

5-Minute Journal Club: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays in the Treatment of Genitourinary Cancers — Issue 1

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. A retrospective analysis of circulating tumor DNA (ctDNA) in the Phase III IMvigor010 study evaluating adjuvant atezolizumab versus observation for muscle-invasive bladder cancer revealed which of the following outcomes?**
 - a. Significantly improved overall survival (OS) among patients with negative ctDNA test results who had received adjuvant atezolizumab
 - b. Significantly improved OS among patients with positive ctDNA test results who had received adjuvant atezolizumab**
 - c. Significantly improved OS among patients who had received adjuvant atezolizumab, regardless of ctDNA status
- 2. Which of the following statements characterizes observations with ctDNA testing for patients during relapse of urothelial bladder cancer?**
 - a. ctDNA positivity constitutes ctDNA levels with any variant allele frequency level above 0
 - b. Patients with high ctDNA levels upon relapse tend to have poorer outcomes than those with low levels**
 - c. The degree of ctDNA level positivity does not correlate with better or worse outcomes
- 3. Which of the following observations was reported in an exploratory ctDNA biomarker analysis of the Phase III KEYNOTE-361 study evaluating first-line pembrolizumab with or without chemotherapy versus chemotherapy alone for advanced urothelial carcinoma?**
 - a. A higher clearance rate and better survival outcomes with chemotherapy alone
 - b. A higher clearance rate with chemotherapy alone but better survival outcomes with immunotherapy**
 - c. A higher clearance rate with immunotherapy but better survival outcomes with chemotherapy alone
 - d. A higher clearance rate and better survival outcomes with immunotherapy
- 4. ctDNA biomarker analysis of the Phase III NIAGARA study evaluating perioperative durvalumab with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone led to which of the following observations?**
 - a. ctDNA clearance predominantly occurs after completion of surgery
 - b. The primary bladder tumor contributes ctDNA in addition to potential metastatic disease at baseline**
 - c. Patients with ctDNA clearance occurring after neoadjuvant chemioimmunotherapy can omit adjuvant durvalumab and retain similar survival outcomes
 - d. Both a and b
 - e. All of the above